Subjects who have systemic infection 
Subjects who have human Immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) 
Subjects who need to take the medicine which is prohibited during this study 
Subjects who have asthma 
Subjects who can not stop treatment with topical steroids (group 1~5), oral antibiotics, whole body photochemotherapy, immunosuppressive drug within 4 weeks before the treatment visit 
Pregnant, breast-feeding women or women who plan to become pregnant during this study (Females of childbearing potential must have a negative urine pregnancy test) 
Subjects who currently participate in other clinical trial or participated in other clinical trial within 30 days 
Subjects who had a serious adverse events during stem cell therapy 
Subjects who had a hypersensitivity to antibiotics or antimycotics 
Subjects who creatinine value is more than two times of the upper limit of the normal range at screening test 
Subjects who aspartate transaminase/alkaline transaminase (AST/ALT) value is more than three times of the upper limit of the normal range at screening test 
Subjects who have any other condition which the investigator judges would make patients unsuitable for study participation       
    

NCT02888704_exc_T1
Condition
systemic infection
NCT02888704_exc_T2
Condition
human Immunodeficiency virus (HIV)
NCT02888704_exc_T3
Condition
hepatitis B virus (HBV)
NCT02888704_exc_T4
Condition
hepatitis C virus (HCV)
NCT02888704_exc_T8
Condition
asthma
NCT02888704_exc_T10
Drug
topical steroids
NCT02888704_exc_T12
Drug
oral antibiotics
NCT02888704_exc_T13
Procedure
whole body photochemotherapy
NCT02888704_exc_T14
Drug
immunosuppressive drug
NCT02888704_exc_T15
Temporal
within 4 weeks before
NCT02888704_exc_T16
Reference_point
treatment visit
NCT02888704_exc_T17
Scope
topical steroids (group 1~5), oral antibiotics, whole body photochemotherapy, immunosuppressive drug
NCT02888704_exc_T18
Condition
Pregnant
NCT02888704_exc_T19
Condition
breast-feeding
NCT02888704_exc_T20
Person
women
NCT02888704_exc_T21
Person
women
NCT02888704_exc_T23
Condition
pregnant
NCT02888704_exc_T24
Temporal
during this study
NCT02888704_exc_T25
Condition
childbearing potential
NCT02888704_exc_T26
Person
Females
NCT02888704_exc_T27
Measurement
urine pregnancy test
NCT02888704_exc_T28
Value
negative
NCT02888704_exc_T29
Scope
Pregnant, breast-feeding
NCT02888704_exc_T33
Condition
serious adverse events
NCT02888704_exc_T34
Temporal
during
NCT02888704_exc_T35
Reference_point
stem cell therapy
NCT02888704_exc_T36
Procedure
stem cell therapy
NCT02888704_exc_T37
Condition
hypersensitivity
NCT02888704_exc_T38
Drug
antibiotics
NCT02888704_exc_T39
Drug
antimycotics
NCT02888704_exc_T40
Scope
antibiotics or antimycotics
NCT02888704_exc_T41
Measurement
creatinine
NCT02888704_exc_T42
Value
more than two times of the upper limit of the normal range
NCT02888704_exc_T43
Temporal
at screening test
NCT02888704_exc_T44
Reference_point
screening test
NCT02888704_exc_T45
Measurement
aspartate transaminase/alkaline transaminase (AST/ALT)
NCT02888704_exc_T46
Value
more than three times of the upper limit of the normal range
NCT02888704_exc_T47
Temporal
at screening test
NCT02888704_exc_T48
Reference_point
screening test
NCT02888704_exc_T49
Condition
any other condition
NCT02888704_exc_T50
Qualifier
the investigator judges would make patients unsuitable for study participation